TY - BOOK ID - 8654947 TI - Multiple myeloma AU - Moehler, Thomas. AU - Goldschmidt, Hartmut. PY - 2011 SN - 3540857710 3540857729 3642267998 PB - Berlin ; Heidelberg : Springer-Verlag, DB - UniCat KW - B cells -- Tumors. KW - Multiple myeloma. KW - Multiple myeloma KW - Hemostatic Disorders KW - Lymphoproliferative Disorders KW - Paraproteinemias KW - Neoplasms, Plasma Cell KW - Blood Protein Disorders KW - Immunoproliferative Disorders KW - Vascular Diseases KW - Neoplasms by Histologic Type KW - Hemorrhagic Disorders KW - Hematologic Diseases KW - Immune System Diseases KW - Cardiovascular Diseases KW - Neoplasms KW - Hemic and Lymphatic Diseases KW - Diseases KW - Multiple Myeloma KW - Medicine KW - Health & Biological Sciences KW - Oncology KW - Treatment KW - B cells KW - Tumors. KW - B cell neoplasia KW - B cell neoplasms KW - B cell tumors KW - B lymphocyte tumors KW - Kahler's disease KW - Plasma cell myeloma KW - Medicine. KW - Cancer research. KW - Hematology. KW - Oncology. KW - Medicine & Public Health. KW - Cancer Research. KW - Tumors KW - Haematology KW - Internal medicine KW - Blood KW - Cancer research KW - Clinical sciences KW - Medical profession KW - Human biology KW - Life sciences KW - Medical sciences KW - Pathology KW - Physicians KW - Lymphomas KW - Monoclonal gammopathies KW - Plasmacytoma KW - Oncology  . UR - https://www.unicat.be/uniCat?func=search&query=sysid:8654947 AB - Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy. In particular, the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide means that multiple myeloma now stands at the forefront of advances in oncology drug development. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life. ER -